PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25996294-9	2015	We validated RIPK1, RIPK3 and transforming growth factor-beta-activated kinase 1 (TAK1) as novel, direct targets of ponatinib by using competitive binding, cellular thermal shift and recombinant kinase assays.	ponatinib	116-125	receptor interacting serine/threonine kinase 1	Homo sapiens	13-18	
25996294-10	2015	Ponatinib inhibited both RIPK1 and RIPK3, while pazopanib preferentially targeted RIPK1.	ponatinib	0-9	receptor interacting serine/threonine kinase 1	Homo sapiens	25-30	
25801024-0	2015	Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.	ponatinib	48-57	receptor interacting serine/threonine kinase 1	Homo sapiens	86-91	
25801024-2	2015	In the current work, we report that the Bcr-Abl inhibitor and anti-leukemia agent ponatinib is also a first-in-class dual inhibitor of RIPK1 and RIPK3.	ponatinib	82-91	receptor interacting serine/threonine kinase 1	Homo sapiens	135-140	
25801024-3	2015	Ponatinib potently inhibited multiple paradigms of RIPK1- and RIPK3-dependent cell death and inflammatory tumor necrosis factor alpha (TNF-alpha) gene transcription.	ponatinib	0-9	receptor interacting serine/threonine kinase 1	Homo sapiens	51-56	
25801024-4	2015	We further describe design strategies that utilize the ponatinib scaffold to develop two classes of inhibitors (CS and PN series), each with greatly improved selectivity for RIPK1.	ponatinib	55-64	receptor interacting serine/threonine kinase 1	Homo sapiens	174-179	
25801024-5	2015	In particular, we detail the development of PN10, a highly potent and selective "hybrid" RIPK1 inhibitor, capturing the best properties of two different allosteric RIPK1 inhibitors, ponatinib and necrostatin-1.	ponatinib	182-191	receptor interacting serine/threonine kinase 1	Homo sapiens	89-94